Вход

Вход на сайт

(Забыли свой пароль?)

Войти

The company's mission «Market Access Solutions»

Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.

 

News

Sort articles by: Date | Most Rates
2232/5000 Pravitel'stvo menyayet pravila lekobespecheniya po programme vysokozatratnykh nozologiy lekarstvennoye obespecheniye, Sem' nozologiy, vysokozatratnyye nozologii, Na regulation.gov.ru razmeshcheno dva proyekta postanovleniya pravitel'stva, kasayushchikhsya izmeneniy lekarstvennogo obespecheniya patsiyentov po programme vysokozatratnykh nozologiy (VZN), izvestnoy kak «Sem' nozologiy». Popravki svyazany s yeye rasshireniyem do 12 VZN. Pervoye postanovleniye pravitel'stva vnosit izmeneniya v neskol'ko normativnykh aktov. Naprimer, v Polozheniye o Minzdrave RF, v perechen' zhizneugrozhayushchikh i khronicheskikh progressiruyushchikh redkikh (orfannykh) zabolevaniy, otkuda isklyuchayutsya gemolitiko-uremicheskiy sindrom, mukopolisakharidoz I tipa, mukopolisakharidoz II tipa, mukopolisakharidoz VI tipa i yunosheskiy artrit s sistemnym nachalom v svyazi s ikh perekhodom v druguyu gosprogrammu. Krome togo, menyayutsya pravila formirovaniya perechney. Preparaty dlya lecheniya pyati vyshenazvannykh nozologiy budut vklyuchat'sya v perechen' dorogostoyashchikh lekarstv v sootvetstvii s protseduroy, kotoraya raneye byla predusmotrena dlya «Semi nozologiy». Vtoroye postanovleniye utverzhdayet novyye pravila lekarstvennogo obespecheniya po programme VZN. Oni ustanavlivayut poryadok i usloviya peredachi Minzdravom i lekarstvennykh preparatov v sobstvennost' sub"yektov Federatsii, a takzhe posleduyushcheye obespecheniye imi nuzhdayushchikhsya grazhdan. Pomimo etogo proyektom postanovleniya zakreplyayetsya ischerpyvayushchiy perechen' svedeniy, soderzhashchikhsya v Federal'nom registre. V nachale avgusta tekushchego goda prezident podpisal Federal'nyy zakon ot 03.08.2018 № 299-FZ «O vnesenii izmeneniy v Federal'nyy zakon «Ob osnovakh okhrany zdorov'ya grazhdan v Rossiyskoy Federatsii». Federal'nym zakonom rasshiryayetsya perechen' zhizneugrozhayushchikh i khronicheskikh progressiruyushchikh redkikh (orfannykh) zabolevaniy, privodyashchikh k sokrashcheniyu prodolzhitel'nosti zhizni ili invalidnosti, dlya lecheniya kotorykh lekarstvennyye preparaty tsentralizovanno zakupayutsya za schet byudzhetnykh assignovaniy federal'nogo byudzheta. Zakon vstupayet v silu s 1 yanvarya 2019 g. Zakupki preparatov dlya novykh pyati zabolevaniya mogut byt' ob"yavlen ne raneye, kak vneseniya vsekh novykh patsiyentov v federal'nyy registr i vklyucheniya neobkhodimykh lekarstv v perechen' dorogostoyashchikh preparatov. Istochnik: pharmvestnik.ru The government changes the rules of medical provision under the program of high-cost nosologies

On regulation.gov.ru there are two draft resolutions of the government concerning the changes in medicinal provision of patients under the high-cost nosology program (VZN), known as the "Seven Nosologies". Corrections are associated with its expansion to 12 VZN.

In the registration documents will make changes to combat "evergreen" patents

Rospatent published a document on amendments to the Rules for drawing up, filing and reviewing documents that are the basis for committing legally significant actions for the state registration of inventions and their forms and Requirements to the documents for an application for the grant of a patent for an invention approved by Order of the Ministry of Economic Development of the Russian Federation of 25 May 2016 No. 316.

Producers of original medicines try to impose restrictions on generics

The general director of AstraZeneca in Russia and Eurasia Irina Panarina proposed to prohibit the registration of the maximum selling price for reproduced medicines before the expiration of the patent for the original drug. She said this at a recent meeting of the committee on the development of the pharmaceutical industry of "Business Russia", Kommersant reports. Such a norm should be introduced into the federal law on the circulation of medicines, the position of the top manager is given. According to Mrs. Panarina, when registering the price, the applicant should also be required to confirm that he does not violate the exclusive rights of third parties.

Dishonest officials will be even more difficult to hide illegal incomes

In August, amendments to strengthen anti-corruption legislation, approved by Federal Law No. 307-FZ of 03.08.2018 "On Amendments to Certain Legislative Acts of the Russian Federation with a view to improving control over compliance with the legislation of the Russian Federation on combating corruption", began to work. The State Duma told why it would become even more difficult for dishonest officials to hide illegal incomes and what they would face for corruption offenses under the new law:

Russian stent-up

Annually about a quarter of deaths in Russia occur due to coronary heart disease (CHD). The main factor in the development of this disease is coronary artery occlusion due to accumulation of cholesterol. One of the most effective ways to treat IHD is coronary artery stenting. The article provides an overview of the state procurement market of Russian-made coronary stents in the Russian Federation over the past three years.

The Ministry of Health intends to speed up the introduction of reproduced drugs on the market

The Ministry of Health of Russia is developing a draft federal law that establishes the responsibility of the holder or holder of the drug's registration certificate for biotechnological and (or) orthopedic medicinal products for the failure to submit samples of such drugs after 4 years from the date of state registration of the drug for clinical trials on a reimbursable basis.